Skip to main content
. 2025 Jan 2;6(1):e70004. doi: 10.1002/mco2.70004

TABLE 3.

The performance of these parameters for predicting CTRCD in derivation and validation cohort.

C‐index (95% confidence interval) p p* p**
Derivation cohort
Age + hypertension + previous cardiovascular disease 0.671 (0.588–0.812) <0.001 0.85 0.43
HFA‐ICOS score 0.642 (0.454–0.716) <0.001 0.081
Maximal apical FD (≥1.272) 0.688 (0.532–0.810) <0.001
LVTFD‐based score 0.834 (0.701–0.932)
Validation cohort
Age + hypertension + previous cardiovascular disease 0.664 (0.503–0.761) <0.001 0.80 0.37
HFA‐ICOS score 0.633 (0.416–0.705) <0.001 0.084
Maximal apical FD (≥1.272) 0.679 (0.521–0.798) <0.001
LVTFD‐based score 0.830 (0.698–0.925)

Note: LVTFD‐based score, the combination of age, hypertension, previous cardiovascular disease, and maximal apical FD by Cox model. p, LVTFD‐based score versus maximal apical FD or HFA‐ICOS score by Delong test; p*, maximal apical FD versus HFA‐ICOS score by Delong test; p**, HFA‐ICOS score versus age + hypertension + previous cardiovascular disease by Delong test.

Abbreviations: CTRCD, cancer therapy–related cardiac dysfunction; FD, fractal dimension; HFA‐ICOS, Heart Failure Association–International Cardio‐Oncology Society; LVTFD, left ventricular trabecular fractal dimension.